These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 1559238)
1. Cancer cell motility-inhibitory protein in the Dunning adenocarcinoma model. Mohler JL; Broskie EN; Ranparia DJ; Sharief Y; Coleman WB; Smith GJ Cancer Res; 1992 Apr; 52(8):2349-52. PubMed ID: 1559238 [TBL] [Abstract][Full Text] [Related]
2. Metastatic potential and substrate dependence of cell motility and attachment in the Dunning R-3327 rat prostatic adenocarcinoma model. Mohler JL; Levy F; Sharief Y Cancer Res; 1991 Dec; 51(24):6580-5. PubMed ID: 1742730 [TBL] [Abstract][Full Text] [Related]
3. Detection of candidates for cancer cell motility inhibitory protein in the Dunning adenocarcinoma model. Mohler JL; Bakewell WE; Sharief Y; Coleman WB; Chay CH; Silvers SM; Smith GJ Clin Exp Metastasis; 1995 Nov; 13(6):474-80. PubMed ID: 7586805 [TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF. Gretzer MB; Chan DW; van Rootselaar CL; Rosenzweig JM; Dalrymple S; Mangold LA; Partin AW; Veltri RW Prostate; 2004 Sep; 60(4):325-31. PubMed ID: 15264244 [TBL] [Abstract][Full Text] [Related]
5. Metastatic potential prediction by a visual grading system of cell motility: prospective validation in the Dunning R-3327 prostatic adenocarcinoma model. Mohler JL; Partin AW; Isaacs JT; Coffey DS Cancer Res; 1988 Aug; 48(15):4312-7. PubMed ID: 3390827 [TBL] [Abstract][Full Text] [Related]
6. Two-dimensional gel electrophoresis of membrane proteins from the R3327 prostate adenocarcinoma. Kozlovskis PL; Claflin AJ; Fletcher MA; McKinney EC; Rubin RW Cancer Res; 1982 Jul; 42(7):2748-56. PubMed ID: 7083165 [TBL] [Abstract][Full Text] [Related]
7. The effect of castanospermine on the metastatic properties of prostate cancer cells. Yee CS; Schwab ED; Lehr JE; Quigley M; Pienta KJ Anticancer Res; 1997; 17(5A):3659-63. PubMed ID: 9413219 [TBL] [Abstract][Full Text] [Related]
8. Overexpression of protein kinase C-zeta (PKC-zeta) inhibits invasive and metastatic abilities of Dunning R-3327 MAT-LyLu rat prostate cancer cells. Powell CT; Gschwend JE; Fair WR; Brittis NJ; Stec D; Huryk R Cancer Res; 1996 Sep; 56(18):4137-41. PubMed ID: 8797581 [TBL] [Abstract][Full Text] [Related]
9. Differential release of active proteinase inhibitors by two rat mammary adenocarcinoma variants possessing different metastatic potentials. Neri A; Bohoslawec O; Anderson TD; Tokes ZA Cancer Res; 1991 Feb; 51(4):1318-25. PubMed ID: 1997170 [TBL] [Abstract][Full Text] [Related]
10. Immunoregulatory markers in rats carrying Dunning R3327 H, G, or MAT-LyLu prostatic adenocarcinoma variants. Rubenstein M; Shaw MW; McKiel CF; Ray PS; Guinan PD Cancer Res; 1987 Jan; 47(1):178-82. PubMed ID: 3491674 [TBL] [Abstract][Full Text] [Related]
11. Flow cytometric assay of pinocytosis: correlation with membrane ruffling and metastatic potential in the Dunning R-3327 rat prostatic adenocarcinoma model. Mohler JL; Sharief Y Cytometry; 1993 Oct; 14(7):826-31. PubMed ID: 8243212 [TBL] [Abstract][Full Text] [Related]
12. The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor. Isaacs JT; Yu GW; Coffey DS Invest Urol; 1981 Jul; 19(1):20-3. PubMed ID: 7251319 [TBL] [Abstract][Full Text] [Related]
14. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Getzenberg RH; Light BW; Lapco PE; Konety BR; Nangia AK; Acierno JS; Dhir R; Shurin Z; Day RS; Trump DL; Johnson CS Urology; 1997 Dec; 50(6):999-1006. PubMed ID: 9426741 [TBL] [Abstract][Full Text] [Related]
15. Identification of nuclear matrix proteins in the cancer and normal rat prostate. Getzenberg RH; Pienta KJ; Huang EY; Coffey DS Cancer Res; 1991 Dec; 51(24):6514-20. PubMed ID: 1742724 [TBL] [Abstract][Full Text] [Related]
16. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Furuya Y; Krajewski S; Epstein JI; Reed JC; Isaacs JT Clin Cancer Res; 1996 Feb; 2(2):389-98. PubMed ID: 9816182 [TBL] [Abstract][Full Text] [Related]
17. Association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of rat prostatic adenocarcinoma. Epner DE; Partin AW; Schalken JA; Isaacs JT; Coffey DS Cancer Res; 1993 May; 53(9):1995-7. PubMed ID: 8481901 [TBL] [Abstract][Full Text] [Related]
18. Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Partin AW; Isaacs JT; Treiger B; Coffey DS Cancer Res; 1988 Nov; 48(21):6050-3. PubMed ID: 3048653 [TBL] [Abstract][Full Text] [Related]
19. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Bussemakers MJ; van Moorselaar RJ; Giroldi LA; Ichikawa T; Isaacs JT; Takeichi M; Debruyne FM; Schalken JA Cancer Res; 1992 May; 52(10):2916-22. PubMed ID: 1581909 [TBL] [Abstract][Full Text] [Related]
20. Contribution of functional voltage-gated Na+ channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: I. Lateral motility. Fraser SP; Salvador V; Manning EA; Mizal J; Altun S; Raza M; Berridge RJ; Djamgoz MB J Cell Physiol; 2003 Jun; 195(3):479-87. PubMed ID: 12704658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]